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ABSTRACT
In December of 2019, an outbreak of a novel coronavirus flared in Wuhan, the capital city of the
Hubei province, China. The pathogen has been identified as a novel enveloped RNA betacoronavirus named SARS-CoV-2. The virus SARS-CoV-2 is associated with a disease

characterized by severe atypical pneumonia known as COVID-19. Typical symptoms of this
disease include cough, fever, malaise, shortness of breath, GI symptoms, anosmia and in severe
cases, pneumonia1. The high-risk group of COVID-19 patients includes people over the age of
60 as well as people with existing cardiovascular disease and/or diabetes mellitus.
Epidemiological investigations have suggested that the outbreak was associated with a live
animal market in Wuhan. Within the first few months of the outbreak, cases were growing
exponentially all over the world. The unabated spread of this deadly and highly infectious virus
is a health emergency for all nations in the world and led to the World Health Organization
(WHO) declaring a pandemic on March 11, 2020. In this report, we consolidate and review the
available clinically and preclinically relevant results emanating from in-vitro, animal models and
clinical studies of drugs approved for emergency use as a treatment for COVID-19 including
remdesivir, hydroxychloroquine, and lopinavir/ritonavir combinations. These compounds have
been frequently touted as top candidates to treat COVID-19, but recent clinical reports suggest
mixed outcomes on their efficacies within the current clinical protocol frameworks.

ABBREVIATIONS: COVID-19 (CoronaVirus Disease-2019); Middle Eastern Respiratory Syndrome
(MERS); Severe Acute Respiratory Syndrome (SARS); Remdesivir (RDV); Hydroxychloroquine (HCQ);
Chloroquine (CQ); Lopinavir-Ritonavir (LPV/r); Acute Respiratory Distress Syndrome (ARDS)

INTRODUCTION

SARS-CoV-2 is a novel beta-coronavirus that has spread to virtually every part of the world.
SARS-CoV-2 is defined as Severe Acute Respiratory Syndrome–CoronaVirus–2. This virus is
characterized by a spherical morphology with several projections represented by the spike (S)
glycoprotein. Several studies have suggested that bats are a likely natural reservoir of SARSCoV-2. This hypothesis has merit, as it is known that various other coronaviruses including
SARS-CoV-1 and MERS-CoV have bats as their natural reservoir2. SARS-CoV-2 shares ~80%
genomic homology with SAR-CoV-1, and ~40% homology with MERS-CoV3. Proteomic
sequencing and phylogenetic analyses showed that similar viral repositories exist in several
animals such as pangolins and turtles, which may serve as intermediate hosts4.

As this is a novel pathogen, there are no vaccines yet developed, nor are there specific antiviral
drugs that have been authorized for use against SARS-CoV-2. The development of novel small
molecules to treat COVID-19 will require an appropriate period of clinical testing before they are
adopted for treatment based on the results of the controlled clinical trials. Thus, there is a critical
need to rapidly identify safe and effective therapies. One of the most promising approaches to
solve this problem is through screening of already approved drugs that can be repurposed for
SARS-CoV-2. This methodology has identified drugs including remdesivir, hydroxychloroquine,
and lopinavir/ritonavir, which all have primary indications as therapies against other pathogens,
but have been recently repurposed for COVID-19 due to lack of specific drugs. Although, invitro studies of these compounds have been promising, the clinical results that will be discussed
later in this paper have been largely inconsistent. Because of this, on March 18, 2020, the WHO
launched a multinational effort examining a number of drugs in clinical trials to evaluate their
efficacy against COVID-19. The standalone drugs or combinations of drugs that are being tested

include remdesivir, a combination of lopinavir and ritonavir, a combination of lopinavir,
ritonavir, and interferon beta, along with chloroquine or hydroxychloroquine. These treatments
regimens will be evaluated relative to appropriate controls, with standard of care including
respiratory support provided as required. It must be noted that even if these compounds exhibit
suboptimal efficacy as stand-alone therapies, there are methods to increase treatment
effectiveness. As our lab has recently proposed, we recommend a multifaceted viral target
approach focusing on combinations of drugs, rather than monotherapy, using approved or
experimental drugs5. We expect that this will not only enhance treatment efficacy, but will also
hamper resistance and adverse effects through targeting multiple essential viral targets
simultaneously. Further in vivo combinatorial testing must be done before using these as
treatments on humans. This paper serves to consolidate the most prominent pre-clinical and
clinical information currently available on these compounds.

Viral Mechanism of Action
As with other coronaviruses, SARS-CoV-2 consists of four structural proteins that comprise a
functional virion. These four proteins are the spike (S), envelope (E), membrane (M), and
nucleocapsid (N) (figure 1). Similar to SARS-CoV-1, the SARS-CoV-2 S protein is a
transmembrane glycoprotein consisting of two major exposed domains, where S1 is responsible
for virus-host binding and S2 induces virus fusion within the endosome6. The S protein of
SARS-CoV-2 uses the same entry receptor as the related SARS-CoV, human angiotensinconverting enzyme 2 (hACE2)7.

Figure 1. Schematic representation of a SARS-CoV-2 virion.
Angiotensin-converting enzyme 2 (ACE2) is the primary host cell receptor responsible for
SARS-CoV attachment and entry. Human ACE2 (hACE2) is present in a wide array of human
tissues: lung epithelia, kidneys, testis and small intestine8. Transmembrane serine protease 2
(TMPRSS2), also found in SARS-CoV, activates/cleaves S proteins to allow for the transmission
of SARS-CoV through ACE2. The S protein consists of three sections: an ectodomain, a singlepass transmembrane anchor, and a short intracellular tail9. The ectodomain of the S protein
consists of two subunits: S1 and S2. The S1 subunit contains a receptor binding domain (RBD)
residing on its C terminus that is involved in binding to ACE210. Like SARS-CoV, SARS-CoV-2
uses ACE2 receptor recognition but with key differences in the binding ridges of its S proteins.
The presence of a unique four-residue motif (glycine-valine/glutamine-glutamate/threonineglycine) with two flexible residues allows for a more compact folding of the ridge11. This results

in closer contact between the S protein and ACE2. In addition, the RBD of the SAR-CoV-2 S
protein is substantially more favorable for ACE2 due to its more hydrophilic environment10.
Both of these differences cause stronger contact and a substantially higher binding affinity
between the S protein and ACE2 in SARS-CoV-2 compared with SARS-CoV. The S2 subunit,
mediates viral membrane fusion with the host cell9. It contains a fusion peptide and two heptad
repeats: the HR1 and HR2 regions. These peptides are presumably responsible for fusion
between viral and host cell membranes.
Coronaviruses are characterized by large (28-32 kb), highly conserved, non-segmented, single
stranded positive-sense RNA (+ssRNA) genomes12. The single strand RNA genome of
coronaviruses is readily translated by host cell machinery, as a 5’ cap as well as a 3’ poly-A tail
flank either side of the genome13. The SARS-CoV genome is translated into polyprotein
products which undergo further processing by viral proteases in the formation of the replicationtranscription complex13. The SARS-CoV-2 +ssRNA genome is composed of 29,903 nucleotides
and its proteome consists of 29 proteins, several of which seem to be druggable14.

REMDESIVIR
Drug Background. Remdesivir (RDV) (figure 2) is a broad spectrum antiviral agent, originally
proposed for Ebola Virus treatment, that has shown antiviral activity against SARS-CoV-1,
MERS-CoV and SARS-CoV-2 in a variety of in vivo and in vitro experiments15–17. The RDV
prodrug is metabolized intracellularly to the active compound RDV (GS-441524), which is a
triphophoramidate adenosine nucleoside analog15,18. Prior in-vitro and in-vivo studies have
identified RDV as having antiviral activity against SARS-CoV-1 and MERS-CoV. RDV
exhibited dose-dependent reduction of SARS-CoV-1 replication in a human airway epithelial

cell line (IC50 = 0.069 µM) 19. Antiviral activity against MERS-CoV was also expressed by RDV
in both human lung epithelial (IC50= 0.025 µM) and human airway epithelial cell lines (IC50 =
0.074 µM). Further, the antiviral activity of RDV against SARS-CoV-1 was analyzed using an in
vivo mouse animal model. RDV was administered to mice at a concentration of 50 mg/kg once a
day or 25 mg/kg twice a day, and either 2 days or 5 days post-infection (dpi). Both RDV
treatment concentrations resulted in a reduced viral load in the lungs of both the 2 dpi and 5 dpi
SARS-CoV-1 infected mice relative to vehicle treated control mice

19

. In vitro assessment was

conducted on RDV-mediated inhibition of MERS-CoV in a Calu-3 human lung epithelial cell
line. RDV displayed potent antiviral activity against MERS-CoV with an EC50 of 0.09 µM. RDV
antiviral ability against MERS-CoV was also assessed via an in vivo mouse model. RDV (25
mg/kg twice a day) administered 24 hours before MERS-CoV infection, resulted in a significant
decrease in viral load, lung hemorrhaging, and mortality relative to vehicle control

19

. The

efficacy of prophylactic and therapeutic RDV treatment in combating MERS-CoV was also
evaluated in a rhesus macaque animal model20. The MERS-CoV infected rhesus macaques were
divided into four groups, a prophylactic experimental group (n=6) that was administered with
RDV (5 mg/kg once a day until 6 dpi) 24 hours before MERS-CoV inoculation, a treatment
experimental group (n=6) that was administered with RDV (5 mg/kg once a day until 6 dpi) 12
hours after MERS-CoV inoculation, a prophylactic control group (n=3) that was administered
with vehicle (1 mL/kg) 24 hours before MERS-CoV inoculation, and a treatment control group
that was administered with vehicle (1 mL/kg) 12 hours after MERS-CoV inoculation.
Prophylactic RDV administration resulted in significant positive clinical outcomes with virtually
no gross or histological lung lesions relative to the control group. Therapeutic RDV
administration resulted in better clinical outcomes and reduced gross and histological lung

lesions relative to the control. Further prophylactic RDV treatment resulted in a significant
reduction in viral load in the lungs relative to control, and a less significant reduction of viral
load in the lungs was also displayed in the therapeutic treatment of RDV relative to the control21.
The antiviral activity of RDV against SARS-CoV-1 and MERS-CoV justified investigation of its
efficacy as a possible treatment for COVID-19. Apparently, as of yet, there have not been
clinical trials testing the antiviral activity of RDV against SARS-CoV-1 or MERS-CoV.

A)

B)

Figure 2. The chemical structure of (A) remdesivir (RDV) and (B) GS-441524

Mechanism of Action Against Coronaviruses. In RDV’s active form, GS-441524 is a
competitive inhibitor of RNA-dependent RNA polymerase (RdRp) by acting as an RNA-chain
terminator, leading to the premature termination of viral RNA transcription15 (figure 3). RDV
incorporation results in termination of RNA transcription three nucleotides from its incorporation
and by escaping proofreading exonuclease activity15. RdRp has a critical role in RNA virus
replication by catalyzing the template synthesis of polynucleotides in the 5’-3’ direction. RdRp is
also essential for the initiation of RNA replication in the host cell, a key step in the RNA viruses
cycle of infection22. RdRp functionality requires SARS-CoV-2 accessory proteins including

Non-Structural Protein (NSP) 7 and NSP 8, which increase template binding23. In SARS-CoV-1,
without RdRp, there is a complete disruption of viral replication, which suggests it importance to
the functionality of the virion24. A recent study has determined the cryo-electron microscopy
structures of the RdRp complex in both, the apo form, and the other in a complex with the
RDV25. This structural analysis further confirms that RDV is a strong inhibitor of RdRp.

Figure 3. Illustration of the SARS-CoV-2 life cycle along with RDV/HCQ/LPV interaction and known
mode of action. The infection cycle starts when SARS-CoV-2 spike protein binds to the human ACE2
receptor. An S1-induced post-stable S2 conformation allows either viral-host cell fusion (1). Fusion
directly allows the viral RNA to enter the host cell, but endocytosis requires lysosomal degradation of
coat and envelope for release of viral nucleocapsid in cytoplasm. HCQ is able to increase the endosomal
and lysosomal pH, inhibiting complete viral endocytosis (2). The SARS-CoV-2 RNA genome is known
to encode 29 viral proteins (3). A replicase is used to translate most of the viral genomic RNA to
synthesize two replicase polyproteins, pp1a and pp1ab. The two major polyproteins are processed by two
proteases, PLpro and 3CLpro, generating 16 nonstructural proteins (4). LPV is thought to inhibit both of

these essential proteases. One of the nonstructural proteins produced by 3CLpro is RNA-dependent-RNApolymerase (RdRp). RdRp is involved in viral-host cell replication through catalyzing template synthesis
of polynucleotides in the 5’ to 3’ direction (5). The active form of RDV (GS-441524) inhibits RdRp,
consequently inhibiting new virion formation. The viral constituents that are created in the host cell are
assembled to form a virion in the endoplasmic reticulum-Golgi apparatus compartment (6). Newly formed
virions are then released from the cell through exocytosis within the smooth vesicles (7).

In vitro testing against SARS-CoV-2. RDV was first confirmed to have antiviral activity
against SARS-CoV-2 from its inhibition of SARS-CoV-2 replication with an EC50 of 0.77 µM17.
Further in vitro studies analyzing RDV ability to inhibit SARS-CoV-2 were performed in Vero
E6 cells16. These in-vitro experiments demonstrated reduction in the viral load of SARS-CoV-2
infected Vero E6 cells with an EC50 of 26.9 µM16. Though wide variation between experiments is
expected, there is an abnormally large 30-fold variation between these two reports. This can
come from sourcing of the drug, improper titration, or other sources of error. More experimental
work must be performed to get a clearer understanding of RDV’s EC50.

Clinical trials and human data. In the first case of a patient presenting with COVID-19 (a 35
year old male) in the U.S., RDV was administered as a compassionate-use antiviral treatment 26.
The SARS-CoV-2 infected patient was a relatively healthy nonsmoker who was admitted to the
hospital on day 5 of illness. By day 10, the patient was given supplemental oxygen due to a
decrease in oxygen saturation levels (90%) and by day 11 of illness, compassionate use of RDV
was administered via infusion. On illness day 12, the clinical outcome measurements improved
in the patient, with an increase in oxygen saturation and a discontinuation of supplemental

oxygen. This case report was published prior to the patient’s discharge26. Clinical findings were
also collected in patients (n=53) with severe COVID-19 who were administered compassionate
use of RDV27. SARS-CoV-2 infected patients who were included in the study had oxygen
saturation levels of 94% or lower, with 64% of patients receiving invasive ventilation. Patients
were treated with RDV (200 mg on day 1 and 100 mg on day 2 to 10) for up to 10 days via
infusion. Upon a median follow-up of 18 days after the first day of RDV treatment (Interquartile
range (IQR) 13-23), improvement in oxygen support was displayed in 68% of patients and a 13%
mortality. Patients receiving invasive ventilation prior to initiation of treatment had a mortality
rate of 18% while patients not receiving invasive ventilation prior to initiation of treatment had a
mortality rate of 5% 27. This work is promising, however these results are impossible to properly
evaluate as they lack a proper control group. In a randomized, double-blinded, placebocontrolled, multicenter clinical trial conducted in 10 hospitals in Hubei, China, RDV efficacy
was analyzed in patients with severe COVID-19 (n=237)

28

. Patients enrolled in the study had

oxygen saturation levels of 94% or less and had displayed symptoms 12 days or fewer prior to
treatment. It is noteworthy that of the COVID-19 patients enrolled in this study, only 0.4% were
on invasive ventilation prior to treatment. SARS-CoV-2 infected patients were randomly
assigned to either an RDV treatment group (n=158) (200 mg on day 1 and 100 mg on day 1 to
10) or a placebo control group (n=78). The time to clinical improvement was not significantly
different between the RDV treatment group and the placebo control group (IQR 13 to 28 vs IQR
15 to 28). Further, no significant difference was observed in the comparison of the 28 day
mortality rate between the RDV treatment group and the placebo control group (14% vs 13%).
Analysis of the 28-day clinical improvement rate found no significant difference between the
two groups; however, mortality was higher in the RDV treatment group (65% vs 58%).

Examination of viral load in the upper and lower respiratory tract also revealed no major
difference between RDV treatment and placebo-dosed control groups

28

. An ongoing

randomized, double blinded, placebo-controlled, clinical trial analyzing the effects of RDV
treatment in patients with severe COVID-19 (n=1063) is currently being conducted by the
United States National Institute of Allergy and Infectious Diseases (NIAID). Patients were
randomly assigned into either an RDV treatment group (200 mg on day 1 and 100 mg on day 210) or into a placebo control group. According to preliminary data from the trial, RDV treatment
results in improved time of clinical improvement in comparison to the placebo control (11 days
vs 15 days). RDV treatment has also been shown in this ongoing study to have resulted in a
decreased mortality rate relative to the placebo control group (8.0% vs 11.6%).

Adverse Effects. As RDV is now authorized for emergency use for COVID-19 in several
countries, any possible adverse effects must be noted. This is especially important in
consideration of RDV relative to the other drugs noted in this paper, because its evaluation
remains in the early stages, and therefore there is limited information available regarding the
adverse effects of RDV that has only been used to treat viral pathogens such as Ebola. Some
notable side effects include, but are not limited to, elevation in hepatic enzymes, diarrhea, and
renal impairment27. The lack of available information constricts our understanding of any
possible adverse effects in the treatment of COVID-19 using RDV. RDV treatment has been
sometimes shown to increase the levels of liver enzymes, which may be a consequence of
inflammation or damage to hepatocytes29. Thus, it is of great importance that before prescribing
RDV to a COVID-19 patient, a proper hematologic/organ specific panel workup must be
performed to test for any preexisting hepatic damage, as well as clinical monitoring during and

after completion of RDV therapy. We are expecting that we will soon have a clearer
understanding of the possible adverse effects on RDV in COVID-19 patients.
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HYDROXYCHLOROQUINE
Drug Background. Chloroquine (CQ) is a 9-aminoquinoline that has been routinely used for the
treatment of malaria and also as an anti-inflammatory drug for systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA). Hydroxychloroquine (HCQ) is an analogue of CQ in which
one of the N-ethyl substituents of CQ is β-hydroxylated (figure 4). The activity of HCQ against
malaria is equivalent to that of CQ, and HCQ is preferred over CQ when high doses are required
because of the lower level of ocular toxicity of HCQ30. The use of HCQ/CQ as an antiinflammatory stems from the compounds’ ability to accumulate in the macrophages and
lymphocytes. Studies in cell lines have shown that the use of HCQ/CQ reduces the secretion of
proinflammatory cytokines and thereby suppressing an excessive host immune reaction31.

A)

B)

Figure 4. The chemical structure of (A) chloroquine (CQ) and (B) hydroxychloroquine (HCQ)

Mechanism of Action Against Coronaviruses. Although CQ and HCQ are widely used
antimalarials, the in vitro antiviral activity of chloroquine has been known since 1969, although
through an unknown mechanism32. Both CQ and HCQ are weak bases that affect vesicles
leading to the dysfunction of several enzymes. The non-protonated conjugated bases of these
compounds are able to enter the host intracellular compartment where they become protonated
and are then trapped as cationic species unable to pass back across the cell membrane. These
compounds are thus concentrated within acidic organelles such as endosomes and lysosomes
where the pH is low 33 (figure 3). CQ and HCQ are cellular autophagy inhibitors that are thought
to interact with enveloped viruses at the late stages of replication

34

. As these compounds are

bases, they increase the pH of lysosomal and trans-Golgi network vesicles which consequently
disrupt several enzymes including acid hydrolases and inhibit the post-translational modification
of newly synthesized proteins34 (figure 3). In the case of SARS-CoV-1, HCQ has also been
shown to interfere with the glycosylation of cellular receptors35, though the exact mechanism and
consequence is not fully understood. CQ/HCQ antiviral activity has been most noted as viruses
enter their target cells through endosome mediated endocytosis. As a virus is endocytosed within
the host cell, it is within the lysosomal compartment where lysosomal enzymes (cathepsin
CSTL) and a low pH unmasks the heptad repeats subdomains of the S2 domain of spike
glycoprotein. The trimer-of-hairpins structure acts as a Class 1 viral fusion protein delivering
nucleocapsid to the cytoplasm. HCQ is known to increase the pH of these lysosomes which then
effectively traps the virion within the vesicle, and it is hypothesized that virions can then be
degraded by lytic enzymes and thus inactivated. Other mechanisms have been proposed for how
HCQ combats viruses. An increase in intracellular Zn2+ saturation and zinc ionophores in the
host cell has been found to inhibit SARS-CoV-1 RNA replication36. HCQ is a zinc ionophore

and induces an increase in intracellular Zn2+ concentration. CQ has been shown to bind to sialic
acid residues, inhibiting the S protein from binding to sialic acid-containing gangliosides37.

In vitro testing against SARS-CoV-2. In early in vitro studies, CQ was found to inhibit SARSCoV-2 infection at micromolar concentration with an EC50 of 1.13 µM and a half-cytotoxic
concentration (CC50) greater than 100 µM17. Shortly after, another group found that HCQ was
even more potent in inhibiting SARS-CoV-2 with an EC50 of 0.72 µM38. HCQ antiviral activity
against SARS-CoV-2 as well as cytotoxicity was measured in an in vitro Vero E6 cell line in
comparison to CQ30. HCQ was found to be more cytotoxic than CQ (CC50 249.50 µM vs CC50
273.20 µM), albeit a more potent antiviral against SARS-CoV-2 relative to CQ (EC50 4.51 µM vs
EC50 2.71 µM). In a time-of-addition assay, HCQ and CQ treatment resulted in the blockage of
viral transport from early endosomes to lysosomes which is essential for SARS-CoV-2 release.
The antiviral efficacy of HCQ in combination with azithromycin was analyzed in SARS-CoV-2
infected Vero E6 cells39. The combination of HCQ/azithromycin was observed to have a
significant inhibition of viral replication (5 µM/5 µM 99.1% viral inhibition and 5 µM/10 µM
97.5% viral inhibition).

Clinical trials and human data. In the case of COVID-19, CQ/HCQ is expected to show
promising results in view of the antiviral effects seen in-vitro testing with these two compounds
and their anti-inflammatory effects. There have been several studies that have demonstrated the
potential efficacy for HCQ as an anti-COVID-19 therapeutic40,41.

In a case study, the clinical outcomes of a SARS-CoV-2 infected patient (39 year old female),
who, due to her rheumatoid arthritis (RA) medical history was already on an oral HCQ treatment
regimen (200 mg a day), were measured42. Upon hospitalization, no treatments specifically
targeting SARS-CoV-2 or inflammatory cascades were administered to the patient other than the
continued use of HCQ. The patient was observed to have mild COVID-19 symptoms and was
discharged from the hospital after two days42. In an uncontrolled, non-comparative clinical
observational study, mild COVID-19 patients (n=80) were administered a HCQ/azithromycin
combination (200 mg oral for 3 times a day for 10 days/500 mg on day 1 and 250 mg on day 24)43. Patients received HCQ/azithromycin treatment for a mean of 4.9 days after onset of illness.
HCQ/azithromycin administration resulted in a promising clinical outcome (81.2% discharge
rate) and low mortality rate (1.2%), but with no control group to compare this to. Further, the
HCQ/azithromycin combination resulted in a decrease in viral load (93% negative at day 8), but
once again, there was no control to compare this to. In a controlled clinical observational study,
HCQ antiviral ability in treating COVID-19 patients (n=1376) at a medical facility in New York
City were analyzed44. SARS-CoV-2 infected patients enrolled in the study had oxygen saturation
levels of 94% or less. Patients (n=811) given an HCQ regimen (600 mg on day 1400 mg on day
2-4) were compared to patients who were given no HCQ (n=565). Patients in the HCQ treatment
group were administered the drug within 48 hours of presentation to the medical facility. It is
essential to note that the HCQ treated patients also differed by baseline characteristics with
patients who did not receive HCQ, including with more severe Acute Respiratory Distress
Syndrome (ARDS) (223 PaO2/FIO2 vs 360 PaO2/FIO2). A time-to-event analysis was conducted
comparing the HCQ treatment group and the no HCQ group with the primary end point defined
as either intubation or mortality. Administration of HCQ was suggested to be associated with a

significant increase in serious complications in comparison to patients given no HCQ (32.3% vs
14.9%) granting a hazard ratio of 2.37 (1.94-3.02 with a 95% confidence interval)44. However,
propensity-score analyses granted a hazard ratio of 1.04 (0.82-1.32 with a 95% confidence
interval) and no major difference was found between HCQ treated patients in comparison to
patients given no HCQ.

In a New York based retrospective, multicenter, clinical observation the antiviral ability of HCQ
as well as HCQ/Azithromycin was analyzed in COVID-19 patients (n=1438; varied baseline
characteristics)45. The SARS-CoV-2 infected patients examined in the study were classified
according to four different treatment groups; HCQ/Azithromycin combination therapy (n=735),
HCQ monotherapy (n=271), Azithromycin monotherapy (n=211), and neither drug (n=221).
HCQ was administered at a median of 1 day and Azithromycin was administered at a median of
0 days after admission. A primary outcome of mortality was analyzed and compared between the
four treatment groups. Treatment of HCQ was suggested to be associated with a higher mortality
rate among COVID-19 patients (HCQ/Azithromycin 25.7%, HCQ 19.9%, Azithromycin 10.0%,
neither drug 12.7%). Although, based on a Cox proportional-hazards model, no notable
difference was present in the mortality rate between the four treatment groups.
HCQ/Azithromycin combination therapy was granted a hazard ratio of 1.35 (0.76-2.40 with a
95% confidence interval), HCQ monotherapy was granted a hazard ratio of 1.08 (0.63-1.85 with
a confidence interval of 95%), Azithromycin monotherapy was granted a hazard ratio of 0.56
(0.26-1.21 with a confidence interval of 95%), in comparison to neither drug45. In a clinical
observation study, HCQ antiviral ability in treating COVID-19 patients requiring supplemental
oxygen (n=173) was examined46. Patients (n=84) administered an HCQ regimen within 48 hours

of admission to the hospital (600 mg once a day) were compared to a control group of patients
(n=89) who were administered no HCQ. The overall survival rate by day 21 was analyzed as
well as the survival rate without transfer to the ICU and the survival rate without ARDS. The
overall survival rate by day 21 of HCQ treated patients exhibited no significant difference in
comparison to the control group that received no HCQ (89% vs 91%). Further, treatment with
HCQ was suggested to have no significant difference in the survival rate without transfer the
ICU by day 21 in comparison to the control group (80% vs 75%). Similarly, no major difference
was found in the survival rate without ARDS between the HCQ treatment group and the no HCQ
control group (70% vs 74%)46.In an open label, multicenter, randomized, controlled clinical trial,
HCQ efficacy in COVID-19 patients was analyzed47. It is notable that of the SARS-CoV-2
infected patients (n=150) enrolled in the study 99% had mild-to-moderate COVID-19. SARSCoV-2 infected patients were randomly assigned to either an HCQ plus standard care treatment
group (n=75) (1200 mg once a day on day 1-3 and 800 mg once a day for up to 14 days) or a
standard care control group (n=75). The negative conversion rate of SARS-CoV-2 was measured
in the COVID-19 patients. Analysis of the 28-day negative conversion rate of SARS-CoV-2
found no significant difference between patients given HCQ plus standard care and patients
given only standard care (85.4% vs 81.3%). Likewise, there was no significant difference found
in the median time to negative conversion between the HCQ plus standard care treatment group
and the standard care control group (8 days vs 7 days)48.

Adverse Effects. The use of CQ/HCQ has been common practice especially in countries
including India and other malaria endemic countries for several decades. These drugs have also
been used in rheumatic and prophylactic conditions which have established a promising safety

profile, where CQ/HCQ treatment showed little or no adverse conditions even during chronic
administration49. However, in case of use for COVID-19, there have been significant adverse
effects associated with CQ/HCQ usage. On April 24, 2020, the United States Food and Drug
Administration (FDA) issued a safety concern regarding the use of CQ/HCQ in COVID-19
patients. This was because of an increased number of reports showing serious heart rhythm
complications in patients treated for COVID-19. This statement came at the moment when
prescriptions for CQ/HCQ for the treatment of COVID-19 were increasing significantly. These
serious cardiovascular complications include QT interval prolongation and ventricular
tachycardia50. A recent clinical observation revealed that a significant number of patients treated
with HCQ or HCQ/azithromycin (n=90) suffered prolonged QTc intervals (23%)51. Further,
HCQ/azithromycin was associated with a greater change of prolonged QTc intervals in
comparison to HCQ monotherapy (median 23 QTc interval milliseconds vs median 5.5 QTc
interval milliseconds)51. Another clinical observation analyzed the safety profile, in regard to
prolonged QTc intervals, of HCQ and HCQ/azithromycin administration in COVID-19 patients
(n=40)52. SARS-CoV-2 infected patients were administered either HCQ monotherapy (n=18) or
HCQ/azithromycin combination therapy (n=22). HCQ administration, with or without
azithromycin, was associated with an increase in QTc intervals (93%) and prolonged QTc
intervals was displayed in a significant portion of treated patients (36%). In the New York based
retrospective, multicenter, clinical observation, HCQ/Azithromycin administration in COVID-19
patients was associated cardiac arrest in comparison to patients given neither drug45.
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LOPINAVIR-RITONAVIR
Drug Background.

Prior in-vitro and clinical studies have shown LPV/r therapeutic regiments to be effective
antivirals in combating SARS-CoV-1. In-vitro analysis of the antiviral ability of LPV/r indicated
successful SARS-CoV-1 inhibition53. Lopinavir (4 µg/mL) and ribavirin (50 µg/mL) attained
successful inhibition of SARS-CoV-1 in a fetal rhesus kidney-4 cell line, after 48 hours of
incubation53. The clinical effectiveness of LPV/r in treating SARS was tested in SARS-CoV-1
infected patients53,54. LPV/r (400 mg/100 mg twice a day) was administered to SARS-CoV-1
patients (n=41) alongside ribavirin and corticosteroids and compared to a matched historical
control group (n=111) which had administered ribavirin alongside a corticosteroid53. The
development of ARDS and mortality was measured in the patients at 21 days. The treatment
group was found to have a drastic decrease in ARDS compared to the control group (2.4% vs
22.5%). Furthermore, the treatment group was found to have a decrease in mortality relative to
the control group (0% vs 6.3%)53. In another clinical study, LPV/r (400 mg/100 mg twice a day)
was administered to two treatment groups, an initial treatment group (n=44) and a rescue
treatment group (n=31), which were compared to corresponding matched historical control
groups (n=634, n=343)54. The rescue group is composed of COVID-19 patients that have already
been administered some other therapy, but the treatment was ineffective. In the initial treatment
of LPV/r in SARS-CoV-1 infected patients, a decrease in the intubation rate (0% vs 11.0%) and
mortality (2.3% vs 15.6%) was found relative to the control group. However, in the rescue
treatment group, no major difference was observed in the intubation rate (9.7% vs 18.1%) or in
mortality (12.9% vs 14.9% ) in SARS-CoV-1 patients in comparison with the control group54.
These findings demonstrated that LPV/r treatment performance in inhibiting SARS-CoV-1 is
diminished in rescue therapy. Mixed success has been found in the LPV/r inhibition of MERSCoV. In a Vero cell line, LPV/r was unable to generate a significant EC50 in inhibiting MERS-

CoV55. However, in the Huh7 cell line LPV/r was able to demonstrate anti-MERS-CoV activity
with an EC50 of 8 µM. In vitro assessment was conducted on the ability of LPV/r and interferon
beta (IFNb) to inhibit MERS-CoV in a Calu-3 human lung cell line19. The LPV/r-IFNb
combination proved to be an inefficient combination, with the addition of LPV/r having no clear
improvement in antiviral activity compared to IFNb alone (EC50 160 IU/mL vs 175 IU/mL)19.
The ability of LPV/r to combat MERS-CoV in vivo has been ambiguous. In a MERS-CoVinfected marmoset animal model, LPV/r administration diminished pathological features and
improved clinical outcomes56. In another in vivo analysis,

LPV/r-IFNb combination was

administered in a mouse animal model19. A therapeutic dose of LPV/r-IFNb was able to improve
pulmonary function, however the combination was not effective in reducing acute lung injury or
viral load19. The relatively potent efficacy demonstrated by LPV/r against SARS-CoV-1 and
MERS-CoV led to the investigation of repurposing LPV/r for SARS-CoV-2 treatment.

Mechanism of Action Against Coronaviruses. The SARS-CoV-1 papain-like cysteine protease
is key in the processing of 16 viral proteins associated with RNA synthesis and proper
replication of the SARS-CoV genome57,58. Since the papain-like protease is critical in SARSCoV-1 replication, it has been a target of interest in SARS-CoV-1 therapies. Lopinavir is a
retroviral protease inhibitor commonly administered in coformulation with the structurally
related ritonavir (LPV/r), a mutagenic guanosine analog which inhibits cytochrome P450
metabolism of lopinavir, in treatment for human immunodeficiency virus (HIV)-118,59 (figure 5).
It has been demonstrated that lopinavir is a noncovalent competitive inhibitor of the SARS-CoV1 papain-like protease59 (figure 3). Further, computational work from our lab predicts that
lopinavir is also able to inhibit SARS-CoV-2 main protease5.

A)

B)

Figure 5. The chemical structure of (A) lopinavir (LPV) and (B) ritonavir (r)

In vitro testing against SARS-CoV-2. In-vitro findings of the antiviral activity of lopinavir and
ritonavir against SARS-CoV-2 infected Vero E6 cells has been encouraging. Lopinavir showed
antiviral activity against SARS-CoV-2 in Vero E6 cells with an EC50 of 26.1 µM16. However,
ritonavir demonstrated optimal antiviral activity against SARS-CoV-2 in Vero E6 cells at a much
higher EC50 of >100 µM16.

Clinical trials and human data. A randomized controlled open-label clinical trial was
conducted in Wuhan, China during the height of the epidemic60. Patients (n=99) infected with
SARS-CoV-2 were randomly assigned into LPV/r treatment (400 mg/100 mg twice a day) or
standard care (n=100) over the course of 14 days. Relatively, no difference was found with the
time of clinical improvement between patients administered LPV/r and patients administered
standard care (16 days vs 16 days). No significant difference was found in the 28-day mortality

rate between patients administered LPV/r and patients administered standard care (19.2% vs
25.0%). Additionally, no major difference was found in the time from randomization to
discharge between patients administered LPV/r and patients administered standard care (12 days
vs 14 days). Further, in the measurement of SARS-CoV-2 throat viral RNA quantification over
the course of the study, LPV/r treatment did not reduce viral RNA loads in comparison to the
standard care group (day 5 34.5% vs. 32.9%, day 10 50.0% vs. 48.6%, day 14 55.2% vs. 57.1%,
day 21 58.6% vs. 58.6%, day 28 60.3% vs. 58.6%)60. In a recent but limited study, the first set of
patients infected with SARS-CoV-2 (n=18) in Singapore was analyzed61. Among the patients
enrolled in the study, 5 patients were on a LPV/r treatment regimen (200 mg/100 mg twice a day
for up to 14 days). Within 3 days of initiation of LPV/r treatment, there was a reduced need for
supplemental oxygen in 3 of those patients. Additionally, within 2 days of initiation of LPV/r
treatment, viral shedding was cleared in 2 of those patients. However, 2 patients who were
administered LPV/r treatment developed respiratory failure within 3 days of initiation of LPV/r
treatment, with 1 patient being admitted to the ICU for assisted ventilation. Therefore, in this
study, LPV/r treatment had no clear effect on decreasing viral load in comparison to patients who
were not treated with LPV/r61. A case study of an index COVID-19 patient in Korea (54-year old
male) assessed the antiviral effectiveness of LPV/r treatment62. Over the course of
hospitalization, the patient experienced mild symptoms of fever and dry cough. The patient
began a LPV/r treatment regimen (two 200 mg or 50 mg pills twice a day) beginning on the 8th
day of hospitalization and 10 days after onset of illness. Starting on the second day of LPV/r
treatment SARS-CoV-2 viral load decreased as well as no detectable virus titers by day 11 of
hospitalization62. However, clinical improvement in the patient could have been the result of a
natural immune response. In a case report a COVID-19 infected patient (61 year old female) with

a history of RA was administered LPV/r therapy along with a continuation of HCQ treatment63.
The SARS-CoV-2 infected patient was admitted to the hospital 4 days after symptom onset. On
day 3 of admission the patient developed an atypical pneumonia. Beginning on day 3 of
admission the patient was administered LPV/r (200 mg or 500 mg twice a day) alongside the
continuation of select RA medications, including HCQ (200 mg once per day). The COVID-19
patient witnessed an improvement in symptoms and inflammatory markers over the course of 10
days after initiation of LPV/r treatment. On day 24 of admission viral load was diminished and
the patient was discharged two days later63. Another small clinical study in Taiwan analyzed
SARS-CoV-2 infected patients (n=5), two of which were administered a LPV/r treatment
regimen (two 200 mg or 50 mg pills twice a day)64. One patient who received LPV/r treatment
was a 56-year-old woman who was administered the treatment on day 5-8 of illness. The patient
underwent adverse gastrointestinal effects, a common side effect of LPV/r treatment, and was
taken off LPV/r treatment by day 8 of illness. The other patient who received LPV/r treatment
was a 53-year-old man who was administered the treatment on days 2-14 of illness. Cycle
threshold (Ct) values were measured and no differences in viral shedding were found as detected
by quantitative reverse transcriptase PCR (qRT-PCR). It was concluded that LPV/r treatment did
not have an effect on shortening SARS-CoV-2 viral shedding, as there was no apparent
differences in the Ct values compared to patients not administered LPV/r (0.9 per day vs 1.0 per
day)64. In contrast, a clinical trial comparing LPV/r-mediated and arbidol-mediated inhibition of
COVID-19 was conducted in Wuhu, China65. SARS-CoV-2 infected patients (n=34) were given
LPV/r treatment (400 mg or 100 mg twice a day) or aribdol (broad spectrum antiviral) (0.2 g
twice a day) (n=16). Patients treated with arbidol showed a drastic decrease in their viral loads
by day 14 in comparison to patients treated with LPV/r (0% vs 44.1%). Patients treated with

arbidol also displayed a reduced duration of positive RNA test days in comparison to patients
treated with LPV/r (9.5 days vs 11.5 days)65.

In a multicenter, open-label, randomized control clinical trial LPV/r combination therapy with
IFNb and ribavirin, was compared to LPV/r monotherapy in COVID-19 patients (n=127)66.
SARS-CoV-2 infected patients with mild-to-moderate COVID-19 symptoms were randomly
assigned to either a triple combination treatment group (n=86) (LPV/r-IFNb-ribavirin) or a
monotherapy control group (n=41) (LPV/r). COVID-19 patients in the treatment group were
administered LPV/r (400 mg/100 mg twice a day), IFNb (3 doses of 8 million IU), and ribavirin
(400 mg twice a day) for 14 days. COVID-19 patients in the control group were administered
LPV/r (400 mg or 100 mg twice a day) for 14 days. The triple combination treatment group
(LPV/r-IFNb-ribavirin) had a decreased time to negative viral load in comparison to the
monotherapy control group (LPV/r) (7 days vs 12 days). Further, improved clinical outcomes
were increased in the triple combination treatment group (LPV/r-IFNb-ribavirin) in comparison
to the monotherapy control group (LPV/r), in both the alleviation of symptoms (4 days vs 8
days) and time to discharge (9.0 days vs 14.5 days)66. In a retrospective, single center study,
discharged COVID-19 patients (n=94) were analyzed67. A select portion of the SARS-CoV-2
infected patients in the retrospective study were on a combination therapy (n=67; unspecified
concentrations) of either IFNa, LPV/r and ribavirin (n=21) or IFNa and LPV/r (n=46). Time to
discharge was correlated with SARS-CoV-2 mRNA conversion time in the IFNa, LPV/r and
ribavirin treatment group (p=0.0215) as well as the IFNa, LPV/r treatment group (p=0.012).
Additionally, no significant difference was found between the two treatment groups in the time
to discharge or the SARS-CoV-2 mRNA conversion times67. In a retrospective, single center

study, the antiviral ability of LPV/r in combination with aribidol was compared to the antiviral
ability of LPV/r monotherapy in SARS-CoV-2 infected patients68. Patients, without invasive
ventilation, were enrolled into the study (n=33) and assigned to either an LPV/r (400mg or 100
mg twice a day) and arbidol (200 mg every 8 hours) combination treatment group (n=16) or an
LPV/r (400 mg or 100 mg twice a day) monotherapy treatment group (n=17). In both the
combination and monotherapy treatment groups, viral load analysis was conducted 7 days and 14
days after initiation of treatment as well as chest CT scans analyzed 7 days after initiation of
treatment. An increase in negative SARS-CoV-2 tests were displayed in the LPV/r-arbidol
combination treatment group in comparison to the LPV/r monotherapy treatment group (day 7:
75% vs 35% negative and day 14: 94% vs 53% negative). Further, the LPV/r-arbidol
combination treatment group was associated with significant improvement in chest CT scans in
comparison to the LPV/r monotherapy group (69% vs 29% improved)68.

A clinical study conducted in Wenzhou, China examined the effectiveness of LPV/r in
combination with pneumonia-associated adjuvant therapy compared to only pneumoniaassociated adjuvant therapy in COVID-19 patients (n=47)69. SARS-CoV-2 infected patients were
assigned to either a treatment group (n=42), administered LPV/r (400 mg or 100 mg twice a day
or 800 mg or 200 mg once a day) alongside pneumonia-associated adjuvant therapy, or a control
group (small, n=5), treated only with pneumonia-associated adjuvant therapy. Daily body
temperatures were monitored and viral load analyses of the COVID-19 patients were analyzed
over the course of 10 days after the initiation of treatment. In the patients whose body
temperature was higher than 37.5°C upon admission, LPV/r treatment in combination with
pneumonia-associated adjuvant therapy was associated with a more rapid return to normal body

temperature in comparison to the control (4.8 days vs 7.3 days). Further, patients treated with
LPV/r alongside pneumonia-associated adjuvant therapy were associated with a shorter time to
testing negative for SARS-CoV-2 RNA in comparison to the control (7.8 days vs 12.0 days)69.

Adverse Effects. In HIV trials, some of the most common adverse effects of LPV/r included
diarrhea, nausea, vomiting, and headaches. There were instances of adverse side effects
including myocardial infarction, pancreatitis, and hepatic failure, which were infrequent (less
than 1%)70. The adverse effects of LPV/r treatment in COVID-19 patients is less understood. The
most common adverse symptoms of LPV/r were altered liver function and gastrointestinal
problems, with varied severity62,71. LPV/r has the potential to interact with a variety of other
drugs through several enzymes70. Some of these drug contradictions include propafenone,
astemizole, flecainide, pimozide, among others70. All of these compounds are highly dependent
on CYP3A or CYP2D6 for clearance, and for which elevated drug plasma concentrations can be
lethal.
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DISCUSSION

The rampant pace of SARS-CoV-2 transmission continues to drastically affect economies and
health systems throughout the world. As this is a novel pathogen, there are no vaccines yet
available, though several are in development and in the trial phase. Also, due to SARS-CoV-2’s
newness and novelty, there are no approved specific antiviral drugs to treat COVID-19.
Furthermore, the discovery and development of novel compounds that specifically target SARSCoV-2 will require a sufficient period of preclinical testing predicting efficacy and safety before
they can enter clinical trials. Thus, the COVID-19 pandemic is a large-scale emergency that
warrants the rapid evaluation and use of already-approved drugs that can be repurposed for
COVID-19. This methodology recommends the use of RDV, CQ/HCQ, and LPV/r to treat
COVID-19 in emergency situations. The use of these drugs is in line with the World Health
Organization’s (WHO) guidance to further repurpose approved drugs that have demonstrated
acceptable safety profiles. There has been widespread international promotion of drugs with
unproven in treating COVID-19 without proper clinical evaluation. Our study has extensively
searched available studies to compile into this review to benefit physicians in making decisions
in treating the COVD-19 patients during this pandemic. Although there are promising outcomes
with statistical significance in some of these clinical trials, many of these trials suggest that
treatment with these drugs are not completely effective in improving recoveries in COVID-19
patients. There are several points that are of utmost importance, as summarized below:

1. Remdesivir (RDV) offers promise as a monotherapy against COVID-19, but the infancy
of the drug makes it impossible to fully understand the adverse effects of this drug in
humans.

2. Further, the prodrug of RDV, GS-441524, relies on cellular metabolic processes for
activation, which makes it possible that there are variable activating processes in various
cell types. This, and the fact that we do not have a complete list of all of the cells and
tissues that are infected by SARS-CoV-2, there may be physiological reservoirs that are
effectively untreatable by RDV.
3. Hydroxychloroquine (HCQ) and chloroquine (CQ) have been the most widely used
treatments for COVID-19. These compounds are effective in blocking SARS-CoV-2 preinfection, but once there is active viral infection within the body, the risks of these drugs
and lack of significant positive clinical impact make them a less desirable treatment
option.
4. As of now, there is no strong evidence for the efficacy of lopinavir-ritonavir (LPV/r)
treatment against COVID-19, although, there is increasing evidence that a LPV/r-IFNbribavirin combination does show promising results for the treatment of COVID-19.
5. Further robust, double-blind, large sampled clinical trials are needed to comprehensively
evaluate suitability of these possible treatments.
6. Additionally, it is of great importance to understand the complete mechanism of action
for each of these compounds to determine the suitability for combination therapy to
increase the likelihood of success given the deficit of specific anti-COVID-19 therapies.
7. We recommend inclusion of more world-approved, as well as experimental drugs, to
assess the possibility of repurposing. Through this, clinicians will be able to identify the
best combinations of compounds that may be of greater efficacy against SARS-CoV-2,
compared to monotherapies.

There is a possibility that these previously-mentioned compounds may earn their place in the
clinical realm as treatments of COVID-19 and may prove to be components of combination
therapy rather than the manner they are currently being utilized. Until a SARS-CoV-2 specific
compound is developed and clinically approved, the most direct way to find a treatment is
through a multifaceted drug-repurposed approach.
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